Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China

JAMA Oncol. 2019 Jan 1;5(1):116-117. doi: 10.1001/jamaoncol.2018.5526.
No abstract available

Publication types

  • Comment

MeSH terms

  • Acrylamides
  • Aniline Compounds
  • Carcinoma, Non-Small-Cell Lung*
  • China
  • Cost-Benefit Analysis
  • ErbB Receptors
  • Humans
  • Indoles
  • Lung Neoplasms*
  • Quinolines

Substances

  • Acrylamides
  • Aniline Compounds
  • Indoles
  • Quinolines
  • anlotinib
  • osimertinib
  • EGFR protein, human
  • ErbB Receptors